Long-term follow-up of BCMA CAR-T cell therapy in patients with relapsed/refractory multiple myeloma

Background B-cell maturation antigen (BCMA)-targeting chimeric antigen receptor (CAR) T-cell immunotherapy has shown promising results in the treatment of relapsed or refractory multiple myeloma (R/RMM). This study presents the updated long-term outcomes from our center.Methods Between July 30, 2018...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Yok-Lam Kwong, Tingting Yang, Guoqing Wei, He Huang, Zhen Cai, Mingming Zhang, Fengmei Song, Yongxian Hu, Yanlei Zhang, Simao Huang, Huijun Xu, Alex H Chang, Jingjing Feng, Jiazhen Cui, Chunxiang Jin, Rongrong Chen, Shan Fu, Yuanyin Teng, Ruimin Hong, Thomas Sau Yan Chan
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMJ Publishing Group 2025-03-01
coleção:	Journal for ImmunoTherapy of Cancer
Acesso em linha:	https://jitc.bmj.com/content/13/3/e010687.full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!